Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel

NCT ID: NCT00028132

Last Updated: 2021-11-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2005-12-31

Brief Summary

The purpose of this study is to evaluate the PMPA gel, which kills microbes, in HIV-infected and HIV-uninfected women.

The majority of new HIV infections occur through heterosexual contact. A product that stops or slows the replication of HIV during sexual contact is needed. At present, there are no products that are completely effective. PMPA gel, also known as tenofovir, is an anti-microbe agent that may fight against sexual transmission of HIV and other sexually transmitted diseases (STDs). It is applied to the vagina and gives women the ability to control their disease-prevention activity.

Detailed Description

The majority of new HIV infections are transmitted through heterosexual contact. Currently, there is no single product that is completely efficacious in preventing initial HIV infection through vaginal transmission. Thus, the development of a topical product which could block local virus replication once infection has occurred is needed. Topical microbicides are designed to prevent the sexual transmission of HIV and other disease pathogens. Potentially, they can be applied vaginally to prevent both male-to-female and female-to-male transmission. They also offer a female-controlled option. PMPA gel has shown some activity against HIV and STD pathogens in in vitro and in vivo laboratory studies.

Participants undergo eligibility screening tests which include: a general physical exam; a pelvic exam; a urine pregnancy test; urinalysis; HIV and STD testing and counseling; and hematology, liver, and renal function tests. For HIV-infected participants, a CD4 cell count is performed and specimens are collected for quantitation of HIV viral load in plasma and cervico-vaginal fluids. [AS PER AMENDMENT 05/29/02: and for HIV resistance genotyping.] PMPA gel is evaluated among 4 types of women distributed into 7 cohorts. All participants apply PMPA gel intravaginally for 14 consecutive intramenstrual days. The dose and frequency of application is escalated across "cohorts." Cohorts A1 through A4 consist of HIV-uninfected, abstinent women who use different doses of PMPA gel once or twice daily. Cohort B includes HIV-uninfected women who are sexually active. Cohorts C and D consist of HIV-infected women who are abstinent or sexually active, respectively. Cohorts B, C, and D use the highest practical dose frequency. The male partners of sexually active participants undergo HIV and STD testing and counseling as well as an optional genital exam and a post-regimen interview. Participants keep a daily record of when doses are taken and of any adverse effects. Pelvic exams, and hematology, liver, and renal function tests (and CD4 cell counts [AS PER AMENDMENT 05/29/02: and resistance genotyping] in HIV-infected participants) are performed at follow-up visits. After the regimen is complete, participants participate in group interviews to discuss adverse effects, adherence to, and general perception of PMPA gel.

The first 6 participants in Cohorts A2, B, and C take part in a pharmacokinetic (PK) study of PMPA gel. Serum collection and PK analysis are performed at different time intervals during 2 study visits.

Conditions

HIV Infections

Keywords

Risk Factors; Mucous Membrane; Anti-Infective Agents; Cervix Uteri; Vagina; Anti-HIV Agents; Pharmacokinetics; Vulva; 9-(2-phosphonylmethoxypropyl)adenine; HIV Seronegativity

Study Design

• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION

Interventions

Tenofovir

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

All female participants may be eligible for this study if they:

• Are between 18 and 45 years of age.
• Have a menstrual cycle with at least 21 days between periods or have not menstruated for at least 6 months.
• Agree from the time of Screening Visit until the Day 14 Follow-up Visit to: a) not use IV drugs (except for therapeutic use) and b) not participate in other microbicide or contraceptive studies.
• Agree not to take part in the following activities for at least 48 hours before the study enrollment visit (Day 0) until the Day 14 Follow-up Visit: anal intercourse; douching; oral contact with the vagina; penetration of the vagina by fingers, sex toys, or any other objects; use of any vaginal product, including lubricants, drying agents, feminine hygiene products, diaphragms, and cervical caps.
• Agree to insert the PMPA gel in the exact way it is specified.
• Abstinent Women (Groups A1-A4, C, and V) may be eligible for this study if they:
• Agree to abstain from vaginal intercourse from 48 hours before study until Day 14.
• HIV-infected abstinent women (C) must be HIV infected; have a CD4 count of at least 200/mm3 at time of screening and within 6 months prior to screening, and a viral load of 10,000 copies/ml or less if on anti-HIV therapy or have a viral load of less than 55,000 if not on anti-HIV therapy; provide study staff access to HIV medical records and be under medical care for HIV management; and be on stable anti-HIV therapy (if any) for 1 month before screening and expect to stay on that therapy throughout the study.
• Sexually Active Women (Groups B and D) may be eligible for this study if they:
• Agree to abstain from vaginal intercourse for 48 hours before study start.
• Agree to tell their mutually monogamous male sexual partner about their participation in the trial and of requirements from Day 0 until Day 14 to have vaginal intercourse at least twice weekly and to use a study-provided male latex condom for every sexual episode.
• HIV-uninfected sexually active women (B) must currently have a single male HIV-uninfected sexual partner who is at low risk for HIV infection and who can be included in the study.
• HIV-infected sexually active women (D) must have a CD4 count of at least 200/mm3 at time of screening and within 6 months prior to screening, and a viral load of 10,000 copies/ml or less if on anti-HIV therapy or have a viral load of less than 55,000 if not on anti-HIV therapy; provide study staff access to HIV medical records and be under medical care for HIV management; be on stable anti-HIV therapy (if any) for 1 month before screening and expect to stay on that therapy throughout the study; and currently have a single male HIV-infected sexual partner who can be included in the study.
• Male sexual partners of sexually active participants (Groups B and D) must be:
• At least 18 years old and in a relationship with the study participant for at least 3 months and be willing to maintain this relationship for the entire study.
• At low risk for HIV infection and be HIV-uninfected if female partner is HIV-uninfected (B) or be HIV-infected if female partner is HIV-infected (D).
• Able and willing to have vaginal intercourse with only the study participant at least 2 times per week, and to use study-provided lubricated male condoms each time during study.
• Willing to not have vaginal intercourse for 48 hours before Day 0.
• Willing to abstain from the following from 48 hours before Day 0 until the end of study product use: anal intercourse, oral contact with the vagina, and penetration of the vagina by fingers, sex toys, or any other objects.
• Willing to take part in an interview after the study and undergo clinical evaluations.
• (This study has been changed to expand the CD4 cell count criterion for Groups C and D.)

Exclusion Criteria

Female participants may not be eligible for this study if they:

• Have gone through menopause.
• Have had a hysterectomy.
• Are breast-feeding.
• Are using or have used within the past year IV drugs (except for therapeutic use).
• Are pregnant.
• Have serious liver, kidney, or blood problems.
• Have had antibiotic therapy in the 14 days before study start.
• Have taken part in other microbicide or contraceptive studies within 1 month of study start.
• Have been previously enrolled in this study.
• Have any genital abnormalities.
• Are sensitive or allergic to any substances used in the study.
• Are unwilling to use 1 of the following methods of contraception during the study unless surgically sterilized: non N-9 condoms, hormonal contraceptives, abstinence.
• Have used any spermicide or condoms that have spermicide on them within 1 week before study start.
• Have used a hormonal contraceptive method for less than 3 months before study start.
• Have had any of the following in the 3 months before study start: vaginal bleeding during or following vaginal intercourse; breakthrough menstrual bleeding; an IUD; an abnormal Pap smear; a pregnancy; an abortion; or gynecologic surgery.
• Have had, in the 6 months before study start, an STD or treatment for any STD, signs of an STD, or signs of genital tract infection.
• Have any other condition that, in the opinion of the doctor, would be unsafe for the participant or would interfere with the study.
• Male sexual partners may not be eligible for this study if they have:
• Been treated for STDs or presumed STDs within 6 months before study start.
• Symptoms of STDs that cannot be evaluated within 2 weeks of study start.
• Sensitivity or allergy to any substance used in the study.
• Any other condition that, in the opinion of the doctor, would be unsafe for the participant or would interfere with the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lisa Maslankowski

Role: STUDY_CHAIR

Kenneth Mayer

Role: STUDY_CHAIR

Locations

Harlem Prevention Ctr. CRS (El-Sadr CTU)

New York, New York, United States

Bronx- Lebanon Hospital Center Clinical Research Site (BLHC CRS)

The Bronx, New York, United States

3535 Market Street CRS

Philadelphia, Pennsylvania, United States

The Miriam Hosp., Div. of Infectious Disease

Providence, Rhode Island, United States

Women & Infants' Hosp.

Providence, Rhode Island, United States

Countries

United States

References

Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006 Feb 28;20(4):543-51. doi: 10.1097/01.aids.0000210608.70762.c3.

Reference Type: RESULT

PMID: 16470118 (View on PubMed)

Carballo-Dieguez A, Balan IC, Morrow K, Rosen R, Mantell JE, Gai F, Hoffman S, Maslankowski L, El-Sadr W, Mayer K. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050). AIDS Care. 2007 Sep;19(8):1026-31. doi: 10.1080/09540120701294237.

Reference Type: RESULT

PMID: 17852000 (View on PubMed)

Other Identifiers

10696

Identifier Type: REGISTRY

Identifier Source: secondary_id

HPTN 050

Identifier Type: -

Identifier Source: org_study_id